Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunovion Pharmaceuticals Inc.

Division of Sumitomo Chemical Co.
www.sunovion.com

Latest From Sunovion Pharmaceuticals Inc.

Japan 2010s In Review: Specialize, Focus, Innovate

Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.

Japan Business Strategies

Dainippon, SanBio Call Time On Stroke Cell Therapy Alliance

Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.

Business Strategies Research and Development Strategies

Keeping Track Of Thanksgiving Leftovers: Risdiplam, Artesunate Highlight Glut Of Submissions/Filings

Yes, we know they should be out of the fridge by now, but here are the highlights of submissions and filings during the Thanksgiving week.

US FDA Performance Tracker Drug Review

Lupin Hit By US Settlement, Japan Injectables Selloff

Despite 10% revenue growth, Lupin ended up with a second-quarter loss from a one-time charge from settling a US lawsuit and the sale of its Japan injectables business. The firm is now counting on levothyroxine and secnidazole to carry it through the next few quarters, amid speculation that it might divest its Japanese subsidiary. 

Sales & Earnings Strategy
See All

Company Information

UsernamePublicRestriction

Register